SCHEMBL4130779

SCHEMBL4130779

CCOC(=O)C(=NO)c1ccccc1CCNCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
ATM Q13315 1/20 0.43
ALDH1A1 P00352 4/20 0.41
TSHR P16473 1/20 0.41
MAPT P10636 2/20 0.40
ABL1 P00519 1/20 0.40
MAPK1 P28482 1/20 0.40
RIN1 Q13671 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.40
SLC6A5 Q9Y345 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
BCHE P06276 1/20 0.39
PPID Q08752 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128786 0.88 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AMEN1ALDH1A1TSHR
SCHEMBL4110227 0.84 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AMEN1ALDH1A1TSHR
SCHEMBL4110223 0.84 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AMEN1ALDH1A1TSHR
SCHEMBL5069975 0.84 MPO (0.54) MPOSMN1; SMN2KMT2AMEN1ATM
SCHEMBL5069973 0.84 MPO (0.54) MPOSMN1; SMN2KMT2AMEN1ATM
SCHEMBL4110253 0.83 GAA (0.43) SMN1; SMN2KMT2AMEN1ATMALDH1A1
SCHEMBL4110251 0.83 GAA (0.43) SMN1; SMN2KMT2AMEN1ATMALDH1A1
SCHEMBL4130782 0.80 MPO (0.47) MPOSMN1; SMN2KMT2AMEN1ATM
SCHEMBL4122757 0.79 TSHR (0.42) SMN1; SMN2KMT2AMEN1ALDH1A1TSHR
SCHEMBL4122756 0.79 TSHR (0.42) SMN1; SMN2KMT2AMEN1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258302-B2 Method for producing benzazepinone API CORPORATION (JP) 2012-09-04 US disclosed
US-20090171090-A1 METHOD FOR PRODUCING BENZAZEPINONE API CORPORATION (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171090-A1 METHOD FOR PRODUCING BENZAZEPINONE NISCH, GABBR1, GABBR2 MPO 1450/4885SMN1; SMN2 3973/4885KMT2A 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.